No adverse event; first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022; first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022; given new booster as second dose; patient was administered their first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 IMMUNISATION (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), INTERCHANGE OF VACCINE PRODUCTS (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), WRONG PRODUCT ADMINISTERED (given new booster as second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient was administered their first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022) and NO ADVERSE EVENT (No adverse event) in a 33-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 062F22A) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer vaccine (first dose) in February 2022. Past adverse reactions to the above products included No adverse event with Pfizer vaccine.    On 03-Nov-2022, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 03-Nov-2022, the patient experienced COVID-19 IMMUNISATION (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), INTERCHANGE OF VACCINE PRODUCTS (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), WRONG PRODUCT ADMINISTERED (given new booster as second dose) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient was administered their first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, COVID-19 IMMUNISATION (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), INTERCHANGE OF VACCINE PRODUCTS (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), WRONG PRODUCT ADMINISTERED (given new booster as second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient was administered their first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for COVID-19 IMMUNISATION (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), INTERCHANGE OF VACCINE PRODUCTS (first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022), WRONG PRODUCT ADMINISTERED (given new booster as second dose) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient was administered their first dose of the Pfizer vaccine in FEB2022 and then dose of the Moderna COVID-19 vaccine bivalent on 3NOV2022).    It was reported that patient had no reported symptoms, no additional doses, medications, or treatments.